Imel Biotherapeutics
PrivateLast Round
Series A
Nov 15, 2021
Total Funding Raised
$15M
Company Overview
Imel Biotherapeutics operates in Healthcare & Life Sciences and is based in Waltham, Massachusetts. Its latest recorded funding round was a Series A round in November 2021.
Imel Biotherapeutics is a biotechnology company that develops cell-based therapies designed to treat patients with mitochondrial disorders and age-related indications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Imel Biotherapeutics Comparables
Compare Imel Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MitoRx Therapeutics | 57% | |
| PAEAN Biotechnology | 57% | |
| Altos Labs | 56% |
For institutional investors. Book with your work email.
Imel Biotherapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Imel Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Shinhan Venture Investment | Series A |
| Korea Investment Partners | Series A |
| Pontifax Venture Capital | Series A |
| Remiges Ventures | Series A |
| Consensus Business Group | Series A |
| Korea Investment Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 15, 2021
$15M round led by Remiges Ventures
For institutional investors. Book with your work email.
Imel Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Imel Biotherapeutics's valuation, stock price, and market status.
Is Imel Biotherapeutics a public or private company?
Imel Biotherapeutics is a private company.
What is the current stock price of Imel Biotherapeutics?
Imel Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Imel Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Imel Biotherapeutics worth (valuation)?
Valuation information for Imel Biotherapeutics is not publicly available.
Can I buy Imel Biotherapeutics stock?
Imel Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Imel Biotherapeutics's last funding round?
Imel Biotherapeutics's most recent funding round was Series A on November 15, 2021.
Who are the main investors in Imel Biotherapeutics?
Key investors in Imel Biotherapeutics include Remiges Ventures.
Will Imel Biotherapeutics IPO soon?
No public IPO plans have been announced for Imel Biotherapeutics.
How can I track Imel Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Imel Biotherapeutics's shares on secondary markets.